Inactive Instrument

Codiak BioSciences

CDAK

US1920101060

Codiak BioSciences, Inc. Bankruptcy Case Dismissed

June 28, 2023 at 12:00 am EDT

The US Bankruptcy Court dismissed the Chapter 11 case of Codiak BioSciences, Inc. on June 28, 2023. The case was dismissed based on the motion filed by Codiak BioSciences, Inc. on June 6, 2023.

Latest news about Codiak BioSciences

Codiak BioSciences, Inc. Bankruptcy Case Dismissed	23-06-28	CI
Motion for Asset Sale Approved for Codiak BioSciences, Inc.	23-06-06	CI
Motion for Case Dismissal Filed by Codiak BioSciences, Inc.	23-06-06	CI
Motion for Asset Sale Approved for Codiak BioSciences, Inc.	23-06-06	CI
Bidding Procedure Approved for Codiak BioSciences, Inc.	23-04-27	CI
Interim Motion for Asset Sale Approved for Codiak BioSciences, Inc.	23-04-12	CI
Motion for Asset Sale Filed by Codiak BioSciences, Inc.	23-04-07	CI
Motion for Asset Sale Filed by Codiak BioSciences, Inc.	23-04-07	CI
Codiak BioSciences, Inc.(OTCPK:CDAK.Q) dropped from NASDAQ Composite Index	23-04-04	CI
Codiak BioSciences, Inc.(NasdaqGM:CDAK) dropped from S&P TMI Index	23-03-30	CI
North American Morning Briefing : Investor Mood -3-	23-03-29	DJ
Motion for Joint Administration Approved for Codiak BioSciences, Inc.	23-03-29	CI
Motion for Joint Administration Filed by Codiak BioSciences, Inc.	23-03-28	CI
Indian Morning Briefing : Asian Markets Rise as Banking Fears Ease	23-03-27	DJ
Health Care Lags Market as Novartis Rises -- Health Care Roundup	23-03-27	DJ
Sector Update: Health Care Stocks Rise in Late Trading	23-03-27	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-03-27	MT
Codiak BioSciences Files for Chapter 11 Bankruptcy, Plans to Sell Assets; Shares Plunge	23-03-27	MT
Codiak BioSciences, Inc. Filed for Bankruptcy	23-03-27	CI
Codiak BioSciences, Inc.(NasdaqGM:CDAK) dropped from NASDAQ Biotechnology Index	22-12-16	CI
Certain Restricted Stock Units of Codiak BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 12-DEC-2022.	22-12-11	CI
Certain Stock Options of Codiak BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 12-DEC-2022.	22-12-11	CI
Certain Common Stock of Codiak BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 12-DEC-2022.	22-12-11	CI
Goldman Sachs Adjusts Price Target on Codiak BioSciences to $1.40 From $2, Maintains Neutral Rating	22-11-07	MT
Codiak BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI

Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx exosomes), focused on treating a range of diseases, including oncology, rare disease and infectious disease. Its product candidates include exoSTING, exoIL-12 and exoASO-STAT6. exoSTING is an exosome therapeutic candidate engineered with its engEx Platform to incorporate its stimulator of interferon genes (STING) agonist inside the lumen of the exosome. exoIL-12 is an exosome therapeutic candidate engineered using its engEx Platform to display IL-12 in a fully active form on the surface via its scaffold protein, prostaglandin F2 receptor negative regulator (PTGRFN).

Sector

More about the company